However, preclinical in vivo studies showed that sst2- and sst3-expressing tumors have higher uptake of radiolabeled SST antagonist, as demonstrated by the evaluation of the labeled antagonist [111In]-DOTA-sst3-ODN-8 in a mouse model bearing sst3 expressing tumor and by in vitro experiments with [111In]-labeled sst2 antagonist DOTA-sst2-ANT ([111In]-DOTA-[4-NO2-Phec(DCys-Tyr-DTrp-Lys-Thr-Cys)-DTyr-NH2 [97, 98]. The gene discussed is SST; the disease is neoplasm.